347 related articles for article (PubMed ID: 19249176)
1. Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
Goldstein EJ; Citron DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):447-54. PubMed ID: 19249176
[TBL] [Abstract][Full Text] [Related]
2. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Wexler HM; Engel AE; Glass D; Li C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
6. Doripenem: position in clinical practice.
Dedhia HV; McKnight R
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
Tanaka K; Mikamo H; Nakao K; Ichiishi T; Goto T; Yamagishi Y; Watanabe K
Antimicrob Agents Chemother; 2009 Jan; 53(1):319-22. PubMed ID: 18955522
[TBL] [Abstract][Full Text] [Related]
8. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Matthews SJ; Lancaster JW
Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Fritsche TR; Stilwell MG; Jones RN
Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections.
Goldstein EJ; Citron DM; Vaidya SA; Warren YA; Tyrrell KL; Vreni Merriam C; Fernandez H
Anaerobe; 2006 Apr; 12(2):63-6. PubMed ID: 16701615
[TBL] [Abstract][Full Text] [Related]
13. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
Jones RN; Bell JM; Sader HS; Turnidge JD; Stilwell MG
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):434-9. PubMed ID: 19302927
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Castanheira M; Jones RN; Livermore DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2008 Feb; 52(2):761-6. PubMed ID: 18070958
[TBL] [Abstract][Full Text] [Related]
16. [Activity of doripenem against anaerobic bacteria].
Dubreuil L; Neut C; Mahieux S; Muller-Serieys C; Jean-Pierre H; Marchandin H; Soussy CJ; Miara A
Pathol Biol (Paris); 2011 Apr; 59(2):102-7. PubMed ID: 20537808
[TBL] [Abstract][Full Text] [Related]
17. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
[TBL] [Abstract][Full Text] [Related]
18. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Goldstein EJ; Snydman DR
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
Schumacher U; Manncke B; Gerbracht K; Werner H
Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
[TBL] [Abstract][Full Text] [Related]
20. Carbapenems in the USA: focus on doripenem.
Lister PD
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
